Cogent Biosciences Raises $230M Through Stock Sale

An update from Cogent Biosciences ( (COGT) ) is now available.

On July 8, 2025, Cogent Biosciences entered into an underwriting agreement to sell 22,222,223 shares of its common stock, raising approximately $230 million. The company announced positive results from the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, showing significant improvements in symptoms and safety profile, with plans to submit a New Drug Application to the FDA by the end of 2025.

The most recent analyst rating on (COGT) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.

Spark’s Take on COGT Stock

According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.

Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.

To see Spark’s full report on COGT stock, click here.

More about Cogent Biosciences

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation, which drives systemic mastocytosis and is also found in advanced gastrointestinal stromal tumors (GIST). The company is based in Waltham, MA, and Boulder, CO.

Average Trading Volume: 2,486,357

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.11B

For detailed information about COGT stock, go to TipRanks’ Stock Analysis page.